<DOC>
	<DOC>NCT01192230</DOC>
	<brief_summary>The purpose of this study is to examine the efficacy and safety of endostatin combined with Docetaxel in advanced Non-Small-Cell Lung Carcinoma (NSCLC) patients failure to first-line or second-line chemotherapy.</brief_summary>
	<brief_title>Study of Endostatin Combined With Docetaxel in the Treatment of Advanced Non-small Cell Lung Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Endostatins</mesh_term>
	<criteria>Patients who were diagnosed by the histologic, cytologic diagnosis of IIIB (malignant hydrothorax or hydropericardium) or IV nonsmall cell lung cancer ≥ 18 years old patients who have received more than one regimen of platinumbased chemotherapy; patients who have received EGFR monoclonal treatment could also be enrolled At least one target lesion diameter spiral CT ≥ 1 cm, or the common CT ≥ 2 cm, and can be measured by imaging tools have an interval of more than 4 weeks from the last chemo or radiotherapy; 2 weeks from the last targeted therapy ECOG 02 Expected life time longer than 3 months Normal laboratory values: leucocyte≥ 4×109/L neutrophil≥ 1.5×109/L platelet≥90×109/L Hemoglobin≥ 9g/L ALT and AST ≤3×ULN (≤5×ULN if liver metastasis) serum creatinine&lt;1.5 mg/dl bilirubin &lt;1.5×ULN No allergy to biological drug Sign the consent forms Patients who have previously received Docetaxel or antiVEGF inhibitors Severe symptomatic heart disease Female patients during their pregnant and lactation period, or patients without contraception Severe uncontrolled infection Uncontrolled neurologic or psychiatric disease; Uncontrolled primary or metastatic brain tumor Patients with other malignant tumor,except for basal cell carcinoma,squamous cell carcinoma and carcinoma in situ Patients have accepted other clinical trials</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Objective response rate</keyword>
	<keyword>Disease control rate</keyword>
	<keyword>Disease free survival</keyword>
	<keyword>Overall survival</keyword>
	<keyword>Quality of Live</keyword>
	<keyword>Nonsmall cell lung cancer</keyword>
	<keyword>toxicity</keyword>
</DOC>